S&P 500   4,564.10 (+0.30%)
DOW   35,500.72 (+0.47%)
QQQ   390.32 (+0.30%)
AAPL   190.78 (+0.52%)
MSFT   382.36 (+0.99%)
META   336.30 (+0.48%)
GOOGL   136.69 (+0.21%)
AMZN   147.22 (-0.35%)
TSLA   241.85 (+2.44%)
NVDA   480.23 (-0.45%)
NIO   7.24 (+0.70%)
BABA   76.14 (-1.79%)
AMD   122.13 (-0.42%)
T   16.16 (-0.31%)
F   10.39 (+0.48%)
MU   75.53 (-2.55%)
CGC   0.53 (-2.45%)
GE   119.67 (-0.25%)
DIS   94.14 (-1.08%)
AMC   6.70 (-1.47%)
PFE   29.96 (-0.60%)
PYPL   57.48 (+1.93%)
XOM   104.81 (+0.82%)
S&P 500   4,564.10 (+0.30%)
DOW   35,500.72 (+0.47%)
QQQ   390.32 (+0.30%)
AAPL   190.78 (+0.52%)
MSFT   382.36 (+0.99%)
META   336.30 (+0.48%)
GOOGL   136.69 (+0.21%)
AMZN   147.22 (-0.35%)
TSLA   241.85 (+2.44%)
NVDA   480.23 (-0.45%)
NIO   7.24 (+0.70%)
BABA   76.14 (-1.79%)
AMD   122.13 (-0.42%)
T   16.16 (-0.31%)
F   10.39 (+0.48%)
MU   75.53 (-2.55%)
CGC   0.53 (-2.45%)
GE   119.67 (-0.25%)
DIS   94.14 (-1.08%)
AMC   6.70 (-1.47%)
PFE   29.96 (-0.60%)
PYPL   57.48 (+1.93%)
XOM   104.81 (+0.82%)
S&P 500   4,564.10 (+0.30%)
DOW   35,500.72 (+0.47%)
QQQ   390.32 (+0.30%)
AAPL   190.78 (+0.52%)
MSFT   382.36 (+0.99%)
META   336.30 (+0.48%)
GOOGL   136.69 (+0.21%)
AMZN   147.22 (-0.35%)
TSLA   241.85 (+2.44%)
NVDA   480.23 (-0.45%)
NIO   7.24 (+0.70%)
BABA   76.14 (-1.79%)
AMD   122.13 (-0.42%)
T   16.16 (-0.31%)
F   10.39 (+0.48%)
MU   75.53 (-2.55%)
CGC   0.53 (-2.45%)
GE   119.67 (-0.25%)
DIS   94.14 (-1.08%)
AMC   6.70 (-1.47%)
PFE   29.96 (-0.60%)
PYPL   57.48 (+1.93%)
XOM   104.81 (+0.82%)
S&P 500   4,564.10 (+0.30%)
DOW   35,500.72 (+0.47%)
QQQ   390.32 (+0.30%)
AAPL   190.78 (+0.52%)
MSFT   382.36 (+0.99%)
META   336.30 (+0.48%)
GOOGL   136.69 (+0.21%)
AMZN   147.22 (-0.35%)
TSLA   241.85 (+2.44%)
NVDA   480.23 (-0.45%)
NIO   7.24 (+0.70%)
BABA   76.14 (-1.79%)
AMD   122.13 (-0.42%)
T   16.16 (-0.31%)
F   10.39 (+0.48%)
MU   75.53 (-2.55%)
CGC   0.53 (-2.45%)
GE   119.67 (-0.25%)
DIS   94.14 (-1.08%)
AMC   6.70 (-1.47%)
PFE   29.96 (-0.60%)
PYPL   57.48 (+1.93%)
XOM   104.81 (+0.82%)

Akebia Therapeutics (AKBA) Earnings Date, Estimates & Call Transcripts

$0.97
-0.02 (-2.32%)
(As of 11:55 AM ET)
Compare
Today's Range
$0.95
▼
$1.00
50-Day Range
$0.80
▼
$1.22
52-Week Range
$0.24
▼
$1.84
Volume
249,884 shs
Average Volume
1.81 million shs
Market Capitalization
$182.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Mar. 14Estimated
Actual EPS
(Nov. 8)
-$0.08 Beat By $0.01
Consensus EPS
(Nov. 8)
-$0.09
Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

AKBA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

AKBA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Akebia Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20232($0.15)($0.11)($0.13)
Q2 20232($0.08)($0.05)($0.07)
Q3 20232($0.07)($0.06)($0.07)
Q4 20232($0.05)($0.04)($0.05)
FY 20238($0.35)($0.26)($0.31)
Q1 20241($0.12)($0.12)($0.12)
Q2 20241($0.11)($0.11)($0.11)
Q3 20241($0.09)($0.09)($0.09)
Q4 20241($0.06)($0.06)($0.06)
FY 20244($0.38)($0.38)($0.38)

AKBA Earnings Date and Information

Akebia Therapeutics last announced its earnings results on November 8th, 2023. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. The company earned $42.05 million during the quarter, compared to analyst estimates of $48.19 million. Akebia Therapeutics has generated ($0.32) earnings per share over the last year (($0.32) diluted earnings per share). Earnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.32) to ($0.29) per share. Akebia Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 14th, 2024 based off prior year's report dates.

Akebia Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
3/14/2024
Estimated)		------- 
11/8/2023Q3 2023($0.09)($0.08)+$0.01($0.08)$48.19 million$42.05 million    
8/25/2023Q2 2023($0.03)($0.06)($0.03)($0.06)$59.10 million$56.38 million    
5/8/2023Q1 2023($0.15)($0.14)+$0.01($0.14)$46.69 million$40.13 million    
3/9/2023Q4 2022($0.14)($0.04)+$0.10($0.04)$48.35 million$55.18 million
11/3/2022Q3 2022($0.15)($0.28)($0.13)($0.28)$47.17 million$48.96 million
8/4/2022Q2 2022($0.31)$0.23+$0.54$0.31$49.10 million$126.76 million    
5/9/2022Q1 2022($0.27)($0.35)($0.08)($0.35)$44.37 million$61.70 million    
3/1/2022Q4 2021($0.33)($0.40)($0.07)($0.40)$48.22 million$59.61 million    
11/4/2021Q3 2021($0.32)($0.34)($0.02)($0.34)$50.09 million$48.76 million    
8/4/2021Q2 2021($0.30)($0.51)($0.21)($0.51)$60.08 million$52.91 million    
5/9/2021Q1 2021($0.33)($0.45)($0.12)($0.45)$43.80 million$52.30 million  
2/24/2021Q4 2020($0.40)($0.60)($0.20)($0.60)$47.86 million$56.70 million  












Akebia Therapeutics Earnings - Frequently Asked Questions

When is Akebia Therapeutics's earnings date?

Akebia Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 14th, 2024 based off last year's report dates. Learn more on AKBA's earnings history.

Did Akebia Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Akebia Therapeutics (NASDAQ:AKBA) reported ($0.08) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.09) by $0.01. Learn more on analysts' earnings estimate vs. AKBA's actual earnings.

How can I listen to Akebia Therapeutics's earnings conference call?

The conference call for Akebia Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Akebia Therapeutics's conference call transcript?

The conference call transcript for Akebia Therapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Akebia Therapeutics generate each year?

Akebia Therapeutics (NASDAQ:AKBA) has a recorded annual revenue of $292.60 million.

How much profit does Akebia Therapeutics generate each year?

Akebia Therapeutics (NASDAQ:AKBA) has a recorded net income of -$94.23 million. AKBA has generated -$0.32 earnings per share over the last four quarters.

What is Akebia Therapeutics's EPS forecast for next year?

Akebia Therapeutics's earnings are expected to grow from ($0.32) per share to ($0.29) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:AKBA) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -